Videx/Videx EC (didanosine): Labeling Revision – Risk of Non-Cirrhotic Portal Hypertension

by FDA on February 6, 2010

in MedWatch

Risk information added to Warnings/Precautions section and data summary provided

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Leave a Comment

Previous post:

Next post: